Baylor Scott & White Research Institute, TGen and OncoHost announce new research study to analyze resistance mechanisms in lung cancer

Jan. 12, 2023
Prospective study aimed at analyzing cancer resistance mechanisms using several multiomics technologies with a follow-up period of up to five years.

Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health; the Translational Genomics Research Institute (TGen), part of City of Hope, a nonprofit biomedical research center; and OncoHost announced a new research study. 

This new, multi-year study will utilize Baylor Scott & White’s Texas Immuno-Oncology Biorepository (TIOB)—which collects, catalogs and stores samples of biological material for cancer research—to analyze resistance mechanisms in cancer using multiomics tools including proteomics, single cell analysis, Ct-DNA, and microbiome analysis combined with bioinformatics and machine learning tools. A comprehensive analysis will be conducted on lung cancer patients at various stages of the disease, analyzing elements such as the host response, the patient’s microbiome, tumor DNA and immune system activity. Testing will look at the patient’s urine, blood, stool, tissue, cells, DNA, RNA, and proteins. The study will include some 350 patients who will receive follow-ups for up to five years.  

The study will utilize OncoHost’s PROphet platform, a plasma-based, proprietary proteomic analysis tool that guides decision-making in the choice of first-line treatment in cancer patients, analyzes resistance mechanisms, and suggests potential treatment combinations to overcome this resistance.  

OncoHost release 

ID 186155466 © Noipornpan | Dreamstime.com
dreamstime_xxl_186155466
ID 310201943 © Oleksandra Tsvid | Dreamstime.com
dreamstime_xxl_310201943
ID 161604768 © Kateryna Kon | Dreamstime.com
dreamstime_xxl_161604768
ID 335528788 © Prostockstudio | Dreamstime.com
dreamstime_xxl_335528788